This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Catalyst Pharmaceuticals Inc.
Drug Names(s): 3,4-Diaminopyridine (3,4-DAP), Zenas (EU), amifampridine phosphate
Description: The active substance of amifampridine phosphate is a potassium channel blocker which increases the release of acetylcholine and helps the muscle to receive the nerve signals. 3,4-Diaminopyridine is an organic compound with the formula C5H3N(NH2)2. It is formally derived from pyridine by substitution of the 3 and 4 positions with an amino group.
Deal Structure: Amifampridine Phosphate was originally developed by Assistance Publique Hopitaux de Paris (AP-HP).
EUSA Pharma acquired the rights to amifampridine from AP-HP.
Huxley licensed the rights to amifampridine from EUSA.
In October 2009, BioMarin acquired Huxley. Under the terms of the agreement, BioMarin paid Huxley stockholders $15.0 million upfront and will pay an additional $7.5 million upon final European Commission approval of amifampridine in LEMS. Additionally, Huxley stockholders are eligible to receive up to approximately $36.0 million in milestone payments. In addition, successful development of multiple sclerosis will result in milestone payments to EUSA.
Jazz and EUSA
In April 2012, Jazz and EUSA announced that the companies have signed a definitive agreement under which Jazz has agreed to acquire EUSA for $650 million in cash and a potential $50 million milestone payable in cash based upon its lead product, Erwinaze (asparaginase Erwinia...See full deal structure in Biomedtracker
Partners: Jazz Pharmaceuticals plc BioMarin Pharmaceutical Inc.
Additional information available to subscribers only: